Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Ai Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -30.00 -6.67% 420.00 424.00 440.00 450.00 430.00 450.00 41,234 16:35:23
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -0.4 -1.0 - 250

Renalytix Ai Share Discussion Threads

Showing 151 to 169 of 175 messages
Chat Pages: 7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
23/5/2020
22:19
Hi Nimbo, I've been doing the same thing and have come to a similar conclusion regarding the medium term valuation. It's got all of the ingredients to be a multi billion pound company, regardless of the additional Covid involvement. - Huge potential market - Game changing technology - Flawless execution to date - Unique relationship with Mount Sinai - High barriers to entry for competitors - Significant and increasingly valuable IP that strengthens their competitive position The main risks are all related to timing, however their strategy of starting the regulatory process at the same time as the clinical studies has reduced the likelihood & potential length of delays. I find it especially intriguing that until 5th May there were securities laws that prevented any US domiciled citizen from owning shares, despite the company being based in America & targeting the US market. Clearly a NASDAQ listing was always in mind, and I can’t help but think they will value RENX shares significantly higher than AIM...
74tom
23/5/2020
16:47
I've been doing a lot of work on renx and come up with some simple numbers at the end of it - if things go right and excluding the covid testing. In 12 months testing capacity is fully utilised - 15,000 tests per month x 12 = 180,000 tests per annum. Revenue from KidneyIntelX is $171,000,000 per annum. (180,000 x $950 price per test). Brokers estimate PBT margin will be 40 % (off much lower revenue forecasts while stating they are conservative). 0.4* 171,000,000 = $68,400,000 PBT. Tax @20% = PAT $54,720,000 * 30PE = $1.6 billion = £1.4 billion £. 1.4/ 0.25 (current market cap) = 5.6X upside if full testing capacity is utilised. (not including covid testing). So this could be a 5 - 10 bagger here on a 2 year view - any opinions on that statement? If I am right this won't stay at this price for too long - might tread sideways a bit but more institutional investors will start to cotton on and the share register is tight. The 2 downsides I have in my excitement are is I my optimistic target assumes testing capacity is utilised quite quickly when I have no insight as to how long it will take to ramp. (However the brokers are only assuming about 25% of the revenue I have mentioned but mention it might be very conservative). I also assume full medicare is passed on the basis of Mount Sinai involvement - I don’t know the risks here.
nimbo1
23/5/2020
13:49
Zak said 650p not 850p. I'll go for the latter.
wantage
23/5/2020
13:44
I'm not a great believer in technical analysisbut good to see Zak Mir, the popular and well known chartistHas aligned with fundamentals and come up with 850p target in his Covid round up.Of all these stocks Renx least speculative as so much else going on. Much rather be here than one drug wonders or outlandish speculative fantasies like Haemogenix.
wantage
21/5/2020
12:28
The key is in the ability to execute at scale...
nimbo1
21/5/2020
12:17
74tom, Not sure there is a huge amount of IP in this. Pricing at $10/test is only likely to attract a lot of competition. At <$5/test, will be hard/impossible/not worth the effort for anyone to dislodge them?
trickydicky1
21/5/2020
07:13
A standard ELISA kit will have 96 wells (12x8). One in each row will be used for test control, so it would be reasonable to assume a kit can undertake 88 tests for a cost of $400.
trickydicky1
20/5/2020
14:31
This is going to be absolutely huge, so many amazing quotes in this press release from Bio-Techne. httPs://www.nasdaq.com/press-release/bio-techne-and-kantaro-biosciences-announce-partnership-to-develop-and-scale "Through Kantaro's partnership with Bio-Techne, we look forward to bringing this extremely high-quality test to every corner of the globe, so that COVID-19 can be monitored and isolated." “As the world leader in ELISA assays, Bio-Techne has substantial capacity and the ability to scale production levels to support much of our nation's needs.” “Initial kit production capacity is expected to enable laboratories to conduct in excess of 10 million tests monthly in July, scaling to higher capacity in subsequent months.”
74tom
20/5/2020
10:58
Bought in this morning, NASDAQ listing alone should see this much higher - it was £3.70 in December.
74tom
20/5/2020
10:33
I'm still here - its also in my 2020 naps
sspurt
20/5/2020
10:30
There are a few of us! (In via Guinness AIM EIS)
toffeeman
20/5/2020
10:10
there is a lot happening here. Nasdaq listing Spin off New business line announced today Also no PI's here it seems...
nimbo1
20/5/2020
09:55
i'm going by the N+1 note this morning and yes, this would be solely to RENX. Although N+1 are being very conservative in their estimates IMO
bubbleandleek
20/5/2020
09:53
I've just been buying a lot more shares. N+1 singer estimate this is a $50 mil additional revenue line for renx annualised as bubbleandleek says. 10 mil tests per month by July @ $400 a test a real possibility... I was here for the other parts of the business but this is an exciting sideline!
nimbo1
20/5/2020
09:28
where do you get the news from ref 4mil a month? would that be to the new venture or renx - renx have 25% of new venture from rns.
nimbo1
20/5/2020
08:49
very quiet on here considering the news today. i hear this could be worth in the region of £4m a month in recurring income..... which will take them past 2021 broker estimates for this alone.... then you have the main part of the business.... and then they haven't even started on the diabetes testing.... oh, and the nasdaq listing!! when all is said and done these could easily be 1500 within the next couple of years. any thoughts?
bubbleandleek
20/5/2020
07:56
http://babblersbestbets.uk/Papers/BabblersEarlyPapers-20th-May-2020/#wbb1
babbler
20/5/2020
07:32
More good news from Renalytix. This time beyond the stated strategy, but importantly utilising the partners combined strengths. In turn, strengthening and demonstrating the important bond.
wan
18/5/2020
09:17
Yes, it seems highly likely that some money will be raised. It will be interesting to see how much or if it's token to provide some liquidity.Presumably the spin off will take place ASAP and before the new listing.
intrinsicinvestor
Chat Pages: 7  6  5  4  3  2  1
ADVFN Advertorial
Your Recent History
LSE
RENX
Renalytix ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200525 10:33:42